| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 03 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT TO TWO-YEAR MILESTONE WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS (this “Amendment”) is entered into as of November 2, 2026, by and among AEON Biopharma, Inc., a Delaware corporation (the “Company”), and each o... |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure
Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / OCTOBER 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Aliso Viejo, Calif., August 3, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic us... |
| 23 Jul 2026 |
8-K: Other Events
As previously reported, on July 15, 2026, AEON Biopharma, Inc. (the “Company”) completed a public offering (the “Offering”), pursuant to an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as r... |
| 15 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
THIS WARRANT AGENCY AGREEMENT (this “Agreement”), dated as of July 15, 2026, is entered into by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporat... |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
AEON Biopharma, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”) as described in the Company’s proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission ... |
| 14 May 2026 |
8-K: Regulation FD Disclosure
Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / MAY 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway - |
| 03 Apr 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
IRVINE, Calif., April 3, 2026 – AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label... |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program |
| 09 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (this “Agreement”), dated as of March 6, 2026, is between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and John Bencich, an individual (“Employee”), effective as of March 9, 2026 (the “Effective... |
| 21 Jan 2026 |
8-K: Unregistered Sales of Equity Securities; Departure/Election of Directors or Officers; Compensation +3 more
The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities a... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Bringing Biosimilar Competition to a U.S. Therapeutic Neurotoxin Market Still Dominated by a Single Brand ABP-450 is being developed as a biosimilar to BOTOX®, aiming to become the first complete therapeutic alternative CORPORATE PRESENT... |
| 15 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Exchange Agreement (this “Agreement”) is dated as of December 15, 2025, between AEON Biopharma, Inc., a Delaware corporation (the “Company”), AEON Biopharma Sub, Inc., a Delaware corporation, as guarantor of the Exchanged Note (as d... |
| 04 Dec 2025 |
8-K: Regulation FD Disclosure
Advancing a Proven Molecule Toward Full-Label Biosimilar Approval Fresh Data | New Capital | Simplified Structure – Positioned for Acceleration CORPORATE PRESENTATION / DECEMBER 2025 NYSEAMERICAN: AEON © 2 0 2 5 A E O N B I O P H A R M A |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth |
| 13 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 12, 2025, by and among AEON Biopharma, Inc, a Delaware corporation (the “Company”), and each of the parties listed on Exhibit A... |
Loading...